Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-parallel Controlled Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of A8G6 COVID-19 Neutralizing Antibody Combination Nasal Spray in Healthy Subjects

NCT06127498 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Chongqing Medical University as lead sponsor.

NCT NCT06127498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06127498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-parallel Controlled Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of A8G6 COVID-19 Neutralizing Antibody Combination Nasal Spray in Healthy Subjects
Lead sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
May 1, 2022
Completion date
December 1, 2023
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prevention, sars-cov-2